SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling...
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial Lead gene therapy asset, SPVN06, reported to be well-tolerated in first...
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach...
Paris, December 1, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) for SPVN06, its lead gene independent therapy for the treatment of retinitis pigmentosa (RP), a form of rod-cone dystrophy (RCD) and the most prevalent inherited retinal disease (IRD). SparingVision has also submitted a clinical trial authorisation (CTA) application to the French regulator (ANSM), which is currently under review.
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa SparingVision set to advance into the clinic with breakthrough gene-independent approach...
Paris, September 14, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that it has raised €75 million in a Series B financing. The round was co-led by Jeito Capital (“Jeito”) and UPMC Enterprises, with additional participation from 4BIO Capital (“4BIO”), Bpifrance, the RD fund, venture arm of Foundation Fighting Blindness (“FFB”), and Ysios Capital (“Ysios”).
Intellia Therapeutics was the first to prove gene editing can work in a human and now the famed CRISPR/Cas9 biotech is beefing up its ocular disease pipeline with a 10% equity stake in SparingVision.
Paris, April 20, 2021 – SparingVision (the “Company”), a genomic medicines company developing vision saving treatments for ocular diseases, today announces it has entered into a definitive agreement to acquire GAMUT Therapeutics (“GAMUT”), a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa (“RP”). The acquisition, subject to legal formalities and approval by shareholders of both companies, will be paid mostly in new SparingVision shares and is expected to close in Q2 2021. Further financial terms of the transaction are not disclosed.
Paris, October 21, 2020 – SparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Enterprises, and included Jeito Capital (“Jeito”) and Ysios Capital (“Ysios”). In addition, current investors Bpifrance and Foundation Fighting Blindness (“FFB”) participated in the round.